                                      UNITED STATES
                           SECURITIES AND EXCHANGE COMMISSION

                                  Washington, DC 20549

                                        FORM 8-K

                                     CURRENT REPORT
         Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

           Date of Report (Date of earliest event reported): November 1, 2007

                                      NEOSTEM, INC.
                 (Exact name of registrant as specified in its charter)

           Delaware                      0-10909                 22-2343568
           --------                      -------                 ----------
        (State Or Other               (Commission              (IRS Employer
        Jurisdiction Of               File Number)           Identification No.)
         Incorporation)

             420 Lexington Avenue, Suite 450
                   New York, New York                              10170
    --------------------------------------------------------------------------------
        (Address of principal executive offices)                 (Zip Code)

                 Registrant's telephone number, including area code: (212)-584-4180

    Check the appropriate box below if the Form 8-K filing is intended to
    simultaneously satisfy the filing obligation of the registrant under any of the
    following provisions (see General Instruction A.2. below):

    [ ]  Written communications pursuant to Rule 425 under the Securities Act (17
         CFR 230.425)

    [ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
         240.14a-12)

    [ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
         Exchange Act (17 CFR 240.14d-2(b))

    [ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
         Exchange Act (17 CFR 240.13e-4(c))

    <PAGE>

    Item 7.01.       Regulation FD Disclosure.

         NeoStem, Inc. (the "Company"), is furnishing presentation materials,
    included as Exhibit 99.1 to this current report and incorporated into this item
    by reference, which will be used by the Company at the Acumen BioFin Rodman and
    Renshaw Healthcare Conference on November 5, 2007.

    Item 9.01.       Financial Statements and Exhibits.

    (d)  Exhibits.

    Exhibit 99.1     Presentation to Investors

    <PAGE>

                                        SIGNATURE
                                        ---------

         Pursuant to the requirements of the Securities Exchange Act of 1934, the
    registrant has duly caused this report to be signed on its behalf by the
    undersigned hereunto duly authorized.

                                        NEOSTEM, INC.

                                        By: /s/ Catherine M. Vaczy
                                            ----------------------------------------
                                            Catherine M. Vaczy
                                            Vice President and General Counsel

    Dated: November 1, 2007